Misplaced Pages

Latanoprostene bunod

Clinical data
Trade names	Vyzulta
Other names	BOL-303259-X
AHFS/Drugs.com	Monograph
License data	US DailyMed: Latanoprostene bunod
Drug class	Prostaglandin analog
ATC code	S01EE06 (WHO)
Legal status
Legal status	CA: ℞-only US: ℞-only
Identifiers
IUPAC name 4-Nitrooxybutyl (Z)-7-cyclopentyl]hept-5-enoate
CAS Number	860005-21-6
PubChem CID	11156438
DrugBank	DB11660
ChemSpider	9331546
UNII	I6393O0922
KEGG	D10441
ChEMBL	ChEMBL2364612
CompTox Dashboard (EPA)	DTXSID101027765
ECHA InfoCard	100.251.571
Chemical and physical data
Formula	C27H41NO8
Molar mass	507.624 g·mol
3D model (JSmol)	Interactive image
SMILES C1(((1O)C/C=C\CCCC(=O)OCCCCO(=O))CC(CCC2=CC=CC=C2)O)O
InChI InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1 Key:LOVMMUBRQUFEAH-UIEAZXIASA-N

Latanoprostene bunod, sold under the brand name Vyzulta, is an ophthalmic medication used for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension. It targets the trabecular meshwork directly. It is a prostaglandin analog.

The most common side effects include conjunctival (eye) redness, eye irritation, and eye discomfort (pain). Latanoprostene bunod may cause the iris (colored part of the eye) to become darker in color.

Latanoprostene bunod was approved for medical use in the United States in November 2017.

Medical uses

Latanoprostene bunod is indicated for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension.

History

The US Food and Drug Administration (FDA) approved latanoprostene bunod based on evidence from two clinical trials that enrolled 840 participants with open angle glaucoma or ocular hypertension. The trials evaluated the benefits and side effects of latanoprostene bunod. In each trial, participants were randomly assigned to receive either latanoprostene bunod or an approved drug timolol (ophthalmic solution) every day for three months. Neither the participants nor the health care providers knew which treatment was being given until after the trials were completed. The trials were conducted in the United States, the United Kingdom, Germany, Italy, Bulgaria, the Czech Republic, and Japan.

References

1. "Regulatory Decision Summary for Vyzulta". Health Canada. 27 December 2018.
2. ^ "Vyzulta- latanoprostene bunod solution/ drops". DailyMed. 1 May 2019. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
3. ^ Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi:10.1007/s40265-018-0914-6. PMC 5976683. PMID 29761382.
4. ^ "Vyzulta". U.S. Food and Drug Administration (FDA). 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024. This article incorporates text from this source, which is in the public domain.
5. "Bausch + Lomb And Nicox Announce FDA Approval Of Vyzulta (Latanoprostene Bunod Ophthalmic Solution), 0.024%" (Press release). Valeant Pharmaceuticals. 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024 – via PR Newswire.

• Medicine

• Ophthalmology drugs
• Prostaglandins
• Triols